Charles Schwab Investment Management Inc Janux Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 234,191 shares of JANX stock, worth $13.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
234,191
Previous 77,516
202.12%
Holding current value
$13.1 Million
Previous $3.25 Million
227.66%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding JANX
# of Institutions
166Shares Held
37.6MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$515 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$142 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$135 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$132 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$116 Million0.17% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.34B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...